Monoclonal Antibodies Market Size - By Type (Fully Human, Humanized, Chimeric), By Application (Oncology, Autoimmune Diseases, Infectious Diseases), By End-use, Global Forecast (2023-2032)
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationMonoclonal Antibodies Market Size - By Type (Fully Human, Humanized, Chimeric), By Application (Oncology, Autoimmune Diseases, Infectious Diseases), By End-use, Global Forecast (2023-2032)
Monoclonal Antibodies Market Size
Monoclonal Antibodies Market size was valued at more than USD 186.6 billion in 2022 and will progress tremendously to reach over USD 609 billion by 2032 at 12.5% CAGR attributing to the increasing prevalence of chronic and infectious diseases, growing research and development activities, high rate of adoption of monoclonal antibodies in the U.S. and Europe
Monoclonal antibodies (mAbs) are referred to the category of proteins having ability to bind to specific cells. These are identical immunoglobulins derived from a single B-cell that recognizes unique binding site on antigen. Due to its specificity to unique epitopes, mAbs are being increasingly used for diagnostic and therapeutic applications for several disease. Currently, large number of monoclonal antibodies are available in the market to treat cancer, cardiovascular diseases, autoimmune diseases, blood disorders, and infectious diseases among others.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Monoclonal Antibodies Market Size in 2022 | USD 186.6 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 12.5% |
| 2032 Value Projection | USD 609 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 135 |
| Tables, Charts & Figures | 238 |
| Segments covered | Type, Application, End-use, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
COVID-19 Impact
The COVID-19 virus outbreak has positively influenced the monoclonal antibodies industry development. Sudden upsurge in number of patients associated with COVID-19 and mortality risk associated with the infection has driven need for effective therapies. Adding to this, several industry players such as Eli Lilly and company and GlaxoSmithKline were continuously involved in development of innovative monoclonal antibodies for prevention and treatment of COVID-19 virus due to its potential to combat disease burden. Moreover, large number of ongoing clinical trials to develop novel drug therapy as well as wide range of product approvals for emergency use in COVID-19 treatment.
Monoclonal Antibodies Driving Factors
The rise in chronic infections and rare diseases is fueling the growth of the monoclonal antibody market. Millions of people worldwide suffer from these serious illnesses. For example, cancer alone claimed 10 million lives in 2020, accounting for one-third of cancer-related deaths globally. Monoclonal antibodies play a vital role in treating many of these diseases, creating a surge in market revenue. Additionally, there's an exciting pipeline of new treatments on the horizon that target a wide range of illnesses. As these therapies gain approval and become more widely available, they will further drive the expansion of the monoclonal antibody market.
Monoclonal Antibodies Market Analysis
The world of monoclonal antibodies (mAbs) is like a puzzle, with different types of mAbs like pieces that fit together to make a whole. There are four main typesfully human, humanized, chimeric, and others. Out of all these types, the fully human mAbs have been the star of the show, dominating the market with over half the pie in 2022. Why are they so popular? Well, it's all about the green light. More and more fully human mAbs are getting the thumbs up from regulators, and new ones are popping up in the market. This means more options for doctors and patients. Thanks to fancy new tech, these fully human mAbs are being discovered and made faster than ever before. And guess what? It's not just about speed - it's also about affordability. With better biotech and cell culture tricks, making these mAbs is cheaper and easier. As a result, the spotlight is shining brighter than ever on fully human mAbs. They're becoming the go-to choice for treating diseases with immunotherapies, which is where you use the body's own immune system to fight back. Plus, using fully human mAbs in animal studies is a breath of fresh air, since there's less risk of confusion and reactions with the animals' own proteins.
Based on application, the monoclonal antibodies market is classified oncology, autoimmune diseases, infectious diseases, and other applications. Oncology segment is anticipated to proceed at 12.6% CAGR by 2032. Monoclonal antibodies are proven effective for targeted treatment of cancer. Moreover, numerous monoclonal antibodies have multiple applications offering advantage of single mAb to target different types of cancers. Moreover, to cater increasing disease burden, key market players are adopting developmental activities.
Based on end-use, the monoclonal antibodies market based on end-use is segmented as hospitals, specialty centres, and other end-uses. Hospitals segment was valued around USD 79.6 billion in 2022 owing to increase in number of patient hospitalizations for range of chronic diseases. Hospitals are well-equipped to manage chronic diseases and other complex medical conditions, and the availability of advanced drug therapies in hospitals has driven patient preference. Highly skilled professionals providing specialty treatments such as cancer and autoimmune diseases drives the product demand in hospitals. Moreover, reimbursement policies for high-cost therapies in hospitals influence the patient visits.
The North American market for monoclonal antibodies is booming, with a whopping 48.8% share in 2022. This surge is driven by the presence of major players in the industry and a steady stream of product approvals. These antibodies are highly sought after for their ability to fight diseases effectively. As healthcare providers adopt them more widely, demand for monoclonal antibodies continues to soar. Research and development (R&D) efforts are also ramping up, with companies and government agencies investing heavily in cancer research. This is leading to the discovery of new and innovative monoclonal antibody treatments. To meet the growing demand, manufacturers are expanding their production capabilities, ensuring a steady supply of these crucial medicines. In the United States and Canada, the approval of more and more monoclonal antibody products is fueling the industry's growth. These advancements have improved access to treatment for patients throughout the region.
Monoclonal Antibodies Market Share
Some of notable key players operating in the monoclonal antibodies market including
- AbbVie Inc.
- F. Hoffmann-La Roche
- Amgen Inc.
- Bristol Myers Squibb
- Johnson & Johnson
- Merck & Co., Inc.
- Regeneron Pharmaceuticals Inc.
- AstraZeneca
- Eli Lilly and Company
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Novartis AG
Monoclonal Antibodies Industry News
- In June 2021, Amgen, Inc. entered in agreement with Kyowa Kirin Co. Ltd., to develop and commercialize KHK4083, a fully human monoclonal antibody for the treatment of atopic dermatitis. Such partnerships have helped the company in business expansion.
- In May 2021, Roche India announced the Emergency Use Authorisation (EUA) for its antibody cocktail by the Central Drugs Standards Control Organisation (CDSCO). This authorization has enabled the company to broaden product accessibility in the country.
The monoclonal antibodies market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
By Type
- Fully human
- Humanized
- Chimeric
- Other types
By Application
- Oncology
- Autoimmune diseases
- Infectious diseases
- Other applications
By End-use
- Hospitals
- Specialty centers
- Other end-uses
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- Singapore
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Egypt
- Kuwait
- Rest of Middle East & Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy